EA201892525A1 - Конструкции днк-антител для применения против pseudomonas aeruginosa - Google Patents
Конструкции днк-антител для применения против pseudomonas aeruginosaInfo
- Publication number
- EA201892525A1 EA201892525A1 EA201892525A EA201892525A EA201892525A1 EA 201892525 A1 EA201892525 A1 EA 201892525A1 EA 201892525 A EA201892525 A EA 201892525A EA 201892525 A EA201892525 A EA 201892525A EA 201892525 A1 EA201892525 A1 EA 201892525A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pseudomonas aeruginosa
- use against
- against pseudomonas
- dna antibody
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
В настоящем документе раскрыты моно- и биспецифические ДНК-антитела (DMAb), нацеленные на Pseudomonas aeruginosa. В настоящем документе также раскрыт способ создания синтетического антитела у субъекта посредством введения субъекту DMAb. В настоящем описании также раскрыт способ предотвращения и/или лечения у субъекта инфекции, вызванной Pseudomonas aeruginosa, с использованием указанной композиции и способа создания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332363P | 2016-05-05 | 2016-05-05 | |
PCT/US2017/031449 WO2017193101A1 (en) | 2016-05-05 | 2017-05-05 | Dna antibody constructs for use against pseudomonas aeruginosa |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892525A1 true EA201892525A1 (ru) | 2019-04-30 |
Family
ID=60203552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892525A EA201892525A1 (ru) | 2016-05-05 | 2017-05-05 | Конструкции днк-антител для применения против pseudomonas aeruginosa |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190153076A1 (ru) |
EP (1) | EP3452090A4 (ru) |
JP (2) | JP2019520085A (ru) |
KR (2) | KR20230093338A (ru) |
CN (1) | CN110072554A (ru) |
AU (1) | AU2017261374A1 (ru) |
BR (1) | BR112018072716A2 (ru) |
CA (1) | CA3023094A1 (ru) |
EA (1) | EA201892525A1 (ru) |
MX (1) | MX2018013525A (ru) |
SG (2) | SG10202011016WA (ru) |
WO (1) | WO2017193101A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3385280A1 (en) | 2011-06-10 | 2018-10-10 | MedImmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
RS60920B1 (sr) * | 2011-11-07 | 2020-11-30 | Medimmune Ltd | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula |
CN111936513A (zh) * | 2018-01-31 | 2020-11-13 | 威斯塔解剖学和生物学研究所 | 用于抗呼吸道合胞病毒的核酸抗体构筑体 |
EP4003421A4 (en) * | 2019-07-31 | 2023-11-08 | The Wistar Institute of Anatomy and Biology | CONSTRUCTIONS OF MULTIVALENT DNA ANTIBODIES AND THEIR USE |
WO2021022113A1 (en) * | 2019-07-31 | 2021-02-04 | The Wistar Institute Of Anatomy And Biology | Multivalent dna antibody constructs and use thereof |
CN114072145A (zh) * | 2020-06-01 | 2022-02-18 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2706732A1 (en) * | 2007-11-30 | 2009-06-11 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
EP3385280A1 (en) * | 2011-06-10 | 2018-10-10 | MedImmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
WO2013026839A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
EP2753362A4 (en) * | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE |
RS60920B1 (sr) * | 2011-11-07 | 2020-11-30 | Medimmune Ltd | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula |
CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
CA2863468A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
JP2015535005A (ja) * | 2012-11-06 | 2015-12-07 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
EA201591131A1 (ru) * | 2012-12-13 | 2015-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Днк-конструкции антитела и способ их применения |
CN105829341A (zh) * | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
-
2017
- 2017-05-05 CA CA3023094A patent/CA3023094A1/en active Pending
- 2017-05-05 EA EA201892525A patent/EA201892525A1/ru unknown
- 2017-05-05 CN CN201780042016.0A patent/CN110072554A/zh active Pending
- 2017-05-05 SG SG10202011016WA patent/SG10202011016WA/en unknown
- 2017-05-05 KR KR1020237019235A patent/KR20230093338A/ko not_active Application Discontinuation
- 2017-05-05 JP JP2019510582A patent/JP2019520085A/ja active Pending
- 2017-05-05 MX MX2018013525A patent/MX2018013525A/es unknown
- 2017-05-05 SG SG11201809778TA patent/SG11201809778TA/en unknown
- 2017-05-05 KR KR1020187035163A patent/KR20190025826A/ko not_active IP Right Cessation
- 2017-05-05 AU AU2017261374A patent/AU2017261374A1/en active Pending
- 2017-05-05 BR BR112018072716-4A patent/BR112018072716A2/pt unknown
- 2017-05-05 US US16/098,908 patent/US20190153076A1/en active Pending
- 2017-05-05 WO PCT/US2017/031449 patent/WO2017193101A1/en unknown
- 2017-05-05 EP EP17793526.9A patent/EP3452090A4/en active Pending
-
2023
- 2023-01-13 JP JP2023003954A patent/JP2023058497A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023058497A (ja) | 2023-04-25 |
US20190153076A1 (en) | 2019-05-23 |
KR20190025826A (ko) | 2019-03-12 |
CN110072554A (zh) | 2019-07-30 |
KR20230093338A (ko) | 2023-06-27 |
BR112018072716A2 (pt) | 2019-02-19 |
SG10202011016WA (en) | 2020-12-30 |
EP3452090A4 (en) | 2019-12-18 |
JP2019520085A (ja) | 2019-07-18 |
MX2018013525A (es) | 2019-06-10 |
WO2017193101A1 (en) | 2017-11-09 |
AU2017261374A1 (en) | 2018-12-20 |
CA3023094A1 (en) | 2017-11-09 |
SG11201809778TA (en) | 2018-12-28 |
EP3452090A1 (en) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
EA201992546A1 (ru) | Средства на основе антител к cd33 | |
EA201890175A1 (ru) | Антитела к cd40 | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
EA201891495A1 (ru) | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза | |
EA201590388A1 (ru) | Способы лечения таупатии | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
EA201891925A1 (ru) | Антитела к cd40 с усиленной агонистической активностью | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
EA201592203A1 (ru) | Способы лечения таупатии | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
PE20190208A1 (es) | Anticuerpos que reconocen tau | |
EA201592285A1 (ru) | Антигенсвязывающие белки к рецептору онкостатина м | |
EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
MX2019011252A (es) | Anticuerpos anti-c5a y usos de los mismos. | |
AU2017310412A8 (en) | Method of improving connective tissue attachment using anti-sclerostin antibodies |